Akebia Therapeutics (AKBA) Research & Development (2017 - 2025)
Historic Research & Development for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to $14.9 million.
- Akebia Therapeutics' Research & Development rose 7608.11% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.5 million, marking a year-over-year increase of 3293.31%. This contributed to the annual value of $37.7 million for FY2024, which is 4030.98% down from last year.
- Akebia Therapeutics' Research & Development amounted to $14.9 million in Q3 2025, which was up 7608.11% from $11.0 million recorded in Q2 2025.
- In the past 5 years, Akebia Therapeutics' Research & Development registered a high of $43.8 million during Q1 2022, and its lowest value of $7.6 million during Q2 2024.
- For the 5-year period, Akebia Therapeutics' Research & Development averaged around $21.8 million, with its median value being $19.7 million (2023).
- As far as peak fluctuations go, Akebia Therapeutics' Research & Development tumbled by 6926.6% in 2023, and later soared by 7608.11% in 2025.
- Quarter analysis of 5 years shows Akebia Therapeutics' Research & Development stood at $29.6 million in 2021, then increased by 8.6% to $32.1 million in 2022, then crashed by 69.27% to $9.9 million in 2023, then grew by 19.47% to $11.8 million in 2024, then grew by 26.79% to $14.9 million in 2025.
- Its Research & Development stands at $14.9 million for Q3 2025, versus $11.0 million for Q2 2025 and $9.8 million for Q1 2025.